SLC5A2 and congestive heart failure: In recent years, angiotensin receptor-neprilysin inhibitor (ARNI) and SGLT2 inhibitor (SGLT2i) drugs have emerged as potent, guideline-recommended medical therapies for patients with chronic heart failure, regardless of their diabetes status [6].